Loading...

Prenetics raises USD10 mn investment led by China's Ping An

Image

16-Mar-16 Prenetics, a precision medicine company focused on personalized, predictive and preventive treatments, has announced a USD10 mn strategic investment led by China's Ping An Ventures. Other investors include Indonesia's Lippo Group backed Venturra Capital, Capital Union Investments and existing investors 500 Startups, COENT Venture Partners. [image: Prenetics]

Read More

Bain Capital enters China

Image

16-Mar-16 Bain Capital LLC is paying USD150 mn for control of China-focused hospital operator Asia Pacific Medical Group, in the first deal for the private-equity firm’s new Asia fund. APMG provides primary care and specialty services, with a focus on neurology and oncology, and has four hospitals in China and a chain of clinics in Singapore and Malaysia. [image: Bain Capital LLC]

Read More

Hong Kong's Evergrande Health Industry links up with Harvard teaching hospital

Image

15-Mar-16 Hong Kong's Evergrande Health Industry has entered into a strategic collaboration with Brigham and Women’s Health Care, a teaching hospital of Harvard Medical School, to develop hospital projects in mainland China. The agreement includes strategic guidance on hospital design, clinical and hospital management and staff training, as well as assistance in developing collaborative hospital projects and planning healthcare service models. [image: Reuters]

Read More

China's ZTE launches its mHealth product

Image

14-Mar-16 "China's ZTE Corp has announced the release of its mHealth product: all-in-one physical examination terminals, with both professional and home editions available.
The health terminal is a multi-parameter instrument with integrated functions for blood pressure, ECG, blood oxygen saturation and urine test, and actively collaborates with a back-end cloud." [image: ZTE]

Read More

China requires generics to obtain brand-name drug quality

Image

08-Mar-16 According to a circular issued by China's State Council, generic drugs already available on the market should be assessed on whether they are consistent with brand-name drugs, and if they could be used clinically. Crucially, generics that pass the assessment will be included under national insurance coverage. [image: People's Daily Online]

Read More
Share